List of Excipients in Branded Drug FLUOROURACIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	FLUOROURACIL	fluorouracil	0378-4791	METHYLPARABEN
Mylan Pharmaceuticals Inc	FLUOROURACIL	fluorouracil	0378-4791	PETROLATUM
Mylan Pharmaceuticals Inc	FLUOROURACIL	fluorouracil	0378-4791	POLYSORBATE 60
Mylan Pharmaceuticals Inc	FLUOROURACIL	fluorouracil	0378-4791	PROPYLENE GLYCOL
Mylan Pharmaceuticals Inc	FLUOROURACIL	fluorouracil	0378-4791	PROPYLPARABEN

Generic Drugs Containing FLUOROURACIL

Company	Ingredient	NDC	Excipient
NORTHSTAR RX LLC	fluorouracil	16714-178	METHYLPARABEN
NORTHSTAR RX LLC	fluorouracil	16714-178	POLYSORBATE 60
NORTHSTAR RX LLC	fluorouracil	16714-178	PROPYLENE GLYCOL
NORTHSTAR RX LLC	fluorouracil	16714-178	PROPYLPARABEN
NORTHSTAR RX LLC	fluorouracil	16714-178	STEARYL ALCOHOL

What are the Most Frequently-Used Excipients in FLUOROURACIL?

# Of NDCs	Excipient
5	CETYL ALCOHOL
2	EDETATE DISODIUM
2	HYDROXYPROPYL CELLULOSE
15	METHYLPARABEN
10	PETROLATUM

Fluorouracil Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Fluorouracil, also called 5-fluorouracil or 5-FU, is an off-patent antimetabolite with two commercially distinct markets: sterile injectable products for oncology and topical products for actinic keratosis and superficial nonmelanoma skin lesions. The active ingredient has limited composition-of-matter value, so commercial differentiation depends on excipient selection, delivery performance, tolerability, packaging, manufacturing reliability, and regulatory positioning.

The strongest opportunities are topical formulations that improve skin deposition and patient adherence without increasing systemic exposure. Injectable products offer lower formulation differentiation but can compete through ready-to-use presentations, supply security, preservative control, and compatibility with oncology administration systems.

What excipients are used in fluorouracil drug products?

Fluorouracil excipients vary substantially by dosage form. Injectable products generally use a simple aqueous system, while topical creams and solutions require excipients that control solubility, viscosity, skin penetration, preservation, spreadability, and patient comfort.

Dosage form	Typical strength	Core excipient functions	Commercial priority
Intravenous injection	50 mg/mL	Water for injection, pH adjustment, buffering or tonicity control where applicable	Supply reliability and ready-to-use administration
Topical cream	0.5%, 4%, or 5%	Emulsion stability, skin hydration, penetration, preservation, sensory profile	Tolerability and adherence
Topical solution	2%	Solubilization, drying time, penetration, preservation	Convenient application and lower residue
Compounded or investigational delivery systems	Variable	Nanocarriers, polymers, lipids, micelles, hydrogels	Improved localization and reduced irritation

FDA-approved fluorouracil injection products use aqueous formulations with pH adjustment, commonly with sodium hydroxide, and are supplied in sterile vials or larger containers. Topical products use more complex vehicles. Depending on the product, excipients can include purified water, propylene glycol, carbomer or other rheology modifiers, stearyl alcohol, polysorbates, emulsifiers, preservatives, and emollients. The exact composition is product-specific and should be taken from the applicable FDA label rather than inferred from the dosage form alone. [1-4]

Which excipients are most commercially relevant in topical fluorouracil?

The highest-value excipient functions are:

1. Controlled skin penetration.
2. Reduced irritation and burning.
3. Stable emulsion or solution performance.
4. Low residue and acceptable cosmetic feel.
5. Consistent dose delivery from the package.
6. Reduced preservative burden.
7. Compatibility with damaged or inflamed skin.

Propylene glycol can act as a solvent, humectant, and penetration enhancer, but it may contribute to stinging or irritant dermatitis in some patients. Carbomers and related polymers control viscosity and residence time. Fatty alcohols and emulsifiers influence spreadability, occlusivity, and sensory characteristics. Surfactants can improve wetting and uniformity but may increase irritation if used at unsuitable levels.

The commercial objective is not maximum permeation. Excessive penetration can increase local inflammation and systemic exposure. A more defensible target is controlled delivery to the epidermal and superficial dermal compartments while limiting unnecessary transport into deeper tissue or circulation.

How does fluorouracil formulation affect clinical and commercial performance?

Fluorouracil produces a predictable local inflammatory response because it damages rapidly proliferating dysplastic and malignant cells. Formulation changes can affect how quickly that response begins, how intense it becomes, and whether patients complete treatment.

A vehicle with high penetration may produce greater lesion response but can also increase pain, erythema, erosion, and treatment discontinuation. A vehicle with lower penetration may be better tolerated but risk inadequate efficacy or inconsistent response. The optimal excipient system therefore balances local exposure and tolerability rather than maximizing either parameter.

Key formulation attributes

Attribute	Desired profile	Commercial effect
Skin deposition	High local deposition with limited systemic absorption	Supports efficacy and safety claims
Irritation	Controlled onset and manageable peak reaction	Improves persistence and refill potential
Spreadability	Uniform coverage with low drag	Reduces dosing variability
Drying time	Rapid enough for daily use	Improves convenience
Residue	Low tack and low visible film	Supports cosmetic acceptability
Stability	Assay and impurity control through shelf life	Reduces recalls and manufacturing losses
Packaging delivery	Consistent dose per actuation or application	Supports product quality and differentiation

The best commercial formulation may not have the highest in vitro flux through excised skin. It may instead demonstrate better lesion-level deposition, lower transepidermal loss, more consistent dosing, and better patient-reported tolerability.

Which fluorouracil dosage forms offer the strongest commercial opportunity?

Topical fluorouracil offers the clearest opportunity for excipient-led differentiation. Injectable fluorouracil is primarily a cost, quality, and availability market.

Topical 4% and 5% creams

Five-percent cream has long been used for actinic keratosis and certain superficial skin cancers. Four-percent products provide a lower-strength alternative and may be positioned around tolerability, treatment convenience, or reduced treatment burden, subject to the approved labeling.

Opportunity areas include:

• Lower-irritation emulsions.
• Improved spreadability over large treatment fields.
• Metered-dose pumps.
• Airless packaging.
• Preservative-reduced systems.
• Non-greasy vehicles.
• Formulations optimized for photodamaged skin.
• Improved stability under temperature excursions.
• More consistent delivery from the first to last dose.

The excipient system can support a differentiated product even where the active ingredient and strength are unchanged. The regulatory claim must remain linked to demonstrated performance. A company cannot assume that a more elegant vehicle permits broader efficacy or safety claims without clinical or comparative data.

Low-strength 0.5% creams

Low-strength formulations, such as 0.5% products, can compete on tolerability and convenience. A lower concentration does not automatically produce lower total exposure because vehicle design, application frequency, treatment area, and skin penetration also matter.

A low-strength formulation with an optimized emulsion may be commercially attractive for patients who are unwilling to use a 5% product because of expected inflammation. The principal development risk is showing that improved tolerability does not materially compromise lesion clearance.

Topical solutions

A 2% solution can offer rapid drying, low residue, and simpler manufacturing than a cream. Solutions are attractive for hairy or irregular areas where cream application is inconvenient. Their disadvantages include potential stinging, evaporation-driven concentration changes, and less forgiving dosing on compromised skin.

Commercial opportunity exists for:

• Low-sting solvent systems.
• Non-drip applicators.
• Metered spray or roll-on delivery.
• Improved control of evaporation.
• Packaging that prevents clogging and dose inconsistency.

Injectable fluorouracil

The injectable market has limited room for excipient innovation because the formulation is chemically simple and clinicians are familiar with established products. Opportunities are concentrated in:

• Ready-to-administer presentations.
• Smaller-volume high-concentration products.
• Terminally sterilized products where feasible.
• Improved container closure systems.
• Reduced adsorption and extractables.
• Standardized compatibility with infusion bags and pumps.
• Reliable supply during oncology drug shortages.
• Barcoded, dose-ready packaging.

Any injectable reformulation must address fluorouracil degradation, container compatibility, particulate control, sterility assurance, and occupational handling. FDA labeling identifies fluorouracil as a hazardous drug, and institutional handling requirements affect product design and packaging. [1, 5]

What excipient technologies can reduce fluorouracil irritation?

The most credible technologies are controlled-release and skin-localizing systems that reduce peak exposure while maintaining sufficient tissue levels.

Emulsion engineering

Oil-in-water emulsions can improve spreadability and reduce the greasy feel associated with heavier ointment systems. Internal-phase composition, droplet size, emulsifier selection, and rheology affect release and skin interaction.

A more occlusive vehicle can increase hydration of the stratum corneum and enhance penetration. That can improve local delivery but may also intensify irritation. Commercial development should measure both pharmacodynamic response and adverse local reaction.

Polymer-based gels and hydrogels

Carbomer, cellulose derivatives, poloxamers, and other polymers can control residence time and release. Hydrogels may be useful when a developer wants a lighter sensory profile than a cream. Their main risks are drying, pilling, poor compatibility with certain preservatives, and insufficient adhesion to irregular skin.

Lipid and vesicular systems

Liposomes, transfersomes, solid lipid nanoparticles, and nanostructured lipid carriers can alter skin deposition and release. These systems may support a patentable formulation platform, but they introduce higher manufacturing and characterization burdens.

Critical development parameters include:

• Particle-size distribution.
• Encapsulation efficiency.
• Active leakage during storage.
• Batch-to-batch reproducibility.
• Scale-up under GMP conditions.
• Demonstration of meaningful clinical benefit.

A nanocarrier is commercially weak if it only produces a novel particle-size profile without improving tolerability, treatment completion, or lesion response.

Cyclodextrins and solubilizers

Cyclodextrins and nonionic solubilizers may improve aqueous handling or solution stability. Their value is greater in solution or low-residue systems than in conventional emulsions. The development team must control local irritation, preservative interactions, and the potential for increased drug flux.

What formulation patents can protect a fluorouracil product?

Fluorouracil's active ingredient is long off patent. Current intellectual-property value lies in formulation, delivery, manufacturing, packaging, and method-of-use claims.

Patentable subject matter

Potential claim categories include:

• Specific excipient ranges.
• Defined oil-to-water ratios.
• Polymer systems with controlled rheology.
• Particle or droplet-size distributions.
• Encapsulation or loading parameters.
• Preservative-free compositions.
• Skin-deposition profiles.
• Reduced-irritation formulations.
• Metered-dose containers.
• Combination products with other dermatologic agents.
• Manufacturing processes that improve impurity control.
• Stability under defined temperature or humidity conditions.

A formulation patent is stronger when it links composition to a measurable technical effect. Examples include a defined reduction in irritation, improved epidermal deposition, improved stability, or consistent delivery over the product's shelf life.

Claims limited to routine substitution of one pharmaceutically acceptable excipient for another may face obviousness challenges. A robust estate usually combines composition claims with process, container, and use claims.

How strong is the patent estate for fluorouracil?

The core fluorouracil patent estate is weak because the active ingredient and conventional dosage forms are mature and generic. The strongest remaining positions are product-specific formulation patents and proprietary delivery systems.

IP layer	Strategic value	Expected durability
Active ingredient	Low	Expired or commercially exhausted
Conventional injectable formulation	Low to moderate	Limited differentiation
Conventional 5% cream	Low to moderate	Vulnerable to generic substitution
Novel topical vehicle	Moderate to high	Depends on claims and clinical evidence
Nanocarrier or controlled-release system	Moderate to high	Stronger if technically non-obvious
Packaging and metering	Moderate	Narrow but commercially useful
Manufacturing impurity-control process	Moderate	Valuable for supply and quality
Method of use	Moderate	Depends on label scope and enforceability

FDA's Orange Book remains relevant for approved fluorouracil products with listed patents or exclusivity, but the status must be assessed by individual reference product and NDA. A generic fluorouracil developer should review current Orange Book entries, FDA approval letters, product labels, and any applicable patent certifications before selecting a launch date. [6]

When does fluorouracil lose exclusivity?

Fluorouracil has already lost meaningful molecular exclusivity. Generic competition is established in both injectable and topical markets.

The practical exclusivity position differs by product:

• The active ingredient is off patent.
• Conventional injectable products are generally exposed to generic competition.
• Established topical strengths face generic or therapeutically substitutable competition.
• Newer branded topical products may retain formulation, regulatory, or market-positioning advantages even without active-ingredient exclusivity.
• Any remaining patent barrier is likely to be product-specific rather than molecule-wide.

The principal launch barriers are therefore regulatory approval, bioequivalence or comparative performance, manufacturing scale, dermatology distribution, and reimbursement rather than basic fluorouracil patent ownership.

What is the FDA regulatory pathway for a new fluorouracil formulation?

A conventional generic product may use an abbreviated new drug application if it meets applicable sameness, quality, and bioequivalence requirements. Topical products can present more complex equivalence questions because vehicle composition affects local delivery.

For topical fluorouracil, development may require:

• Pharmaceutical equivalence.
• Comparative physicochemical characterization.
• In vitro release testing.
• In vitro permeation testing.
• Comparative clinical endpoint studies or other FDA-accepted equivalence approaches.
• Microbiological quality and preservative-effectiveness data.
• Container-closure performance.
• Stability data.

FDA's product-specific guidance should govern the selected development pathway. [7] A formulation with materially different excipients may not qualify for the simplest generic route, particularly if the differences affect drug release, local exposure, or safety.

A new drug application may be more suitable where the product has a novel delivery mechanism, clinically meaningful tolerability benefit, or a distinct indication. That route offers more flexibility but requires substantially greater clinical and regulatory investment.

Which companies can compete in the fluorouracil market?

Competition comes from three groups:

1. Generic manufacturers supplying injectable and topical products.
2. Branded dermatology companies selling differentiated topical formulations.
3. Specialty formulation developers pursuing controlled-release or patient-friendly delivery systems.

Generic injectable competition is primarily driven by price, manufacturing reliability, and hospital contracting. Dermatology competition is more sensitive to patient experience, prescriber preference, pharmacy substitution, and access.

A company entering topical fluorouracil should avoid competing solely on active-ingredient price. The more defensible strategy is to combine a differentiated vehicle with:

• A clear tolerability message.
• A convenient application system.
• Specialty-pharmacy or dermatology distribution.
• Evidence supporting treatment completion.
• Packaging that reduces waste and contamination.
• A focused indication and prescriber segment.

What manufacturing and supply-chain barriers affect fluorouracil excipients?

The active ingredient is inexpensive relative to development and commercial execution. Excipients can become the limiting factor when a formulation uses specialized polymers, lipid systems, high-purity surfactants, or proprietary packaging components.

Key barriers include:

• Multiple-source qualification for critical excipients.
• Control of peroxide and aldehyde impurities in excipients.
• Compatibility between preservatives and polymeric thickeners.
• Scale-up of emulsions without changing droplet size.
• Control of microbial burden in aqueous topical products.
• Tube, pump, and liner compatibility.
• Container extractables and leachables.
• Stability after repeated opening.
• Cold-chain or temperature-excursion sensitivity.
• Reliable supply of specialty-grade polymers or lipids.

For injectables, the preferred strategy is usually excipient simplification. Each additional excipient increases compatibility, extractables, and regulatory review requirements without necessarily creating commercial value.

What are the most attractive commercial opportunities?

Opportunity 1: Lower-irritation topical cream

A 4% or 5% cream with improved tolerability, reduced residue, and consistent skin deposition has the strongest near-term opportunity. The product should be evaluated against an established comparator using local reaction scores, treatment completion, patient-reported outcomes, and lesion clearance.

Opportunity 2: Preservative-reduced or preservative-free packaging

Airless pumps and unit-dose systems can reduce contamination risk and improve product presentation. The business case is strongest when the packaging also improves dose consistency and reduces waste.

Opportunity 3: Hair-bearing-area solution or spray

A non-drip solution or metered applicator could address practical limitations of cream use. The development focus should be application uniformity, stinging, drying time, and dose reproducibility.

Opportunity 4: Controlled-release lipid or polymer system

This offers the highest patent potential but also the greatest technical risk. Commercial viability requires evidence that the system produces a meaningful clinical advantage rather than a merely novel formulation profile.

Opportunity 5: Hospital-ready injectable presentation

Ready-to-use or dose-efficient injectable fluorouracil can compete in oncology procurement if it reduces pharmacy preparation, handling, or waste. The value proposition depends on validated stability, container compatibility, and institutional purchasing economics.

What generic entry risks exist for a differentiated fluorouracil product?

A differentiated fluorouracil product remains exposed to substitution if its approval is therapeutically interchangeable with low-cost generics. The main risks are:

• Generic creams with similar strengths and indications.
• Compounding pharmacies serving niche formulations.
• Physician reluctance to pay for vehicle differentiation.
• Payer noncoverage of branded topical products.
• Patent claims limited to narrow excipient ranges.
• Clinical evidence that does not demonstrate superior tolerability.
• Manufacturing complexity that raises cost above reimbursement.

A formulation company should therefore design the product around a measurable economic outcome, such as fewer discontinuations, lower treatment failure, fewer follow-up visits, or improved adherence. Excipient novelty without a payer-relevant benefit is unlikely to sustain premium pricing.

Key Takeaways

• Fluorouracil is an off-patent small molecule; commercial value comes from formulation and delivery.
• Topical products offer more differentiation potential than injectable products.
• The leading excipient objective is controlled local skin delivery with lower irritation, not maximum permeation.
• High-value excipient platforms include optimized emulsions, hydrogels, lipid carriers, and metered-dose packaging.
• Injectable fluorouracil is primarily a supply, quality, and presentation opportunity.
• Formulation patents should connect defined excipient compositions to measurable technical or clinical effects.
• Generic entry risk is high for conventional creams, solutions, and injections.
• The strongest business case combines excipient innovation with adherence, tolerability, packaging, and reimbursement evidence.
• Fluorouracil has no biosimilar risk because it is a chemically synthesized small molecule, not a biologic.
• Current Orange Book and product-specific FDA records must control any launch or freedom-to-operate assessment.

FAQs

Can propylene glycol improve fluorouracil skin penetration?

Yes. Propylene glycol can function as a solvent, humectant, and penetration enhancer. Its concentration must be balanced against the risk of stinging and irritant dermatitis, especially on inflamed or eroded skin.

Is a fluorouracil liposome automatically patentable?

No. Liposomal delivery may support patent protection only when the composition, process, or performance is sufficiently novel and non-obvious. A measurable improvement in stability, skin deposition, tolerability, or treatment outcome strengthens the position.

Can an airless pump create market exclusivity for fluorouracil?

An airless pump alone rarely creates broad exclusivity. It can support narrow device or container claims and may improve dose consistency, contamination control, and product presentation.

Does a lower fluorouracil concentration guarantee better tolerability?

No. Tolerability depends on concentration, vehicle, penetration, application area, dosing frequency, treatment duration, and patient skin condition. A lower-strength product can still produce substantial inflammation if its vehicle increases local exposure.

Is injectable fluorouracil suitable for a preservative-free product?

Yes. Many injectable fluorouracil products use relatively simple aqueous systems without a conventional antimicrobial preservative. The product still requires validated sterility, container-closure integrity, stability, and compatibility data.

References

1. U.S. Food and Drug Administration. (2023). Fluorouracil injection prescribing information. FDA.
2. U.S. Food and Drug Administration. (2023). Efudex (fluorouracil) cream and solution prescribing information. FDA.
3. U.S. Food and Drug Administration. (2023). Carac (fluorouracil) cream prescribing information. FDA.
4. U.S. Food and Drug Administration. (2023). Tolak (fluorouracil) cream prescribing information. FDA.
5. National Institute for Occupational Safety and Health. (2023). NIOSH list of hazardous drugs in healthcare settings. Centers for Disease Control and Prevention.
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
7. U.S. Food and Drug Administration. (2024). Product-specific guidances for generic drug development. FDA.